Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peng Zhan

Showing results (1-10 of 558) with videos related to

Pageof 56
Sort By:
Current Pharmaceutical Design|June 13, 2009
Designed multiple ligands: an emerging anti-HIV drug discovery paradigmPeng Zhan, Xinyong Liu
Expert Opinion on Therapeutic Patents|April 5, 2011
Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010)Peng Zhan, Xinyong Liu
Frontiers in Public Health|November 21, 2022
The impact of agricultural disasters on child development in rural ChinaSipei Xu, Peng Zhan
Current Pharmaceutical Design|July 18, 2013
Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activitiesYu'ning Song, Peng Zhan, Xinyong Liu
Science Bulletin|January 20, 2023
Reducing energy barriers of chemical reactions with a nanomicrocell catalyst consisting of integrated active sites in conductive matricesGuo-Peng Zhan, Chuan-De Wu
International Journal of Genomics|October 1, 2025
NRG-1 Promotes Axon Regeneration of Dorsal Root Ganglion Neurons in Diabetic Rats via ITGB1/FAK/AKT PathwayPeng Zhan, Hewei Xiong, Hongmei Zheng
Mini Reviews in Medicinal Chemistry|April 23, 2010
Naturally occurring and synthetic bioactive molecules as novel non-nucleoside HBV inhibitorsPeng Zhan, Xuemei Jiang, Xinyong Liu
Mini Reviews in Medicinal Chemistry|June 15, 2010
Cosalane and its analogues: a unique class of anti-HIV agentsPeng Zhan, Zhenyu Li, Xinyong Liu
Current Medicinal Chemistry|August 20, 2009
Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 updatePeng Zhan, Xinyong Liu, Zhenyu Li
Journal of Medicinal Chemistry|March 28, 2019
Resurrecting the Condemned: Identification of N-Benzoxaborole Benzofuran GSK8175 as a Clinical Candidate with Reduced Metabolic LiabilityPeng Zhan, Dongwei Kang, Xinyong Liu
Pageof 56

Showing results (1-10 of 558) with videos related to

Sort By:
Pageof 56
Current Pharmaceutical Design|June 13, 2009
Designed multiple ligands: an emerging anti-HIV drug discovery paradigmPeng Zhan, Xinyong Liu
Expert Opinion on Therapeutic Patents|April 5, 2011
Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010)Peng Zhan, Xinyong Liu
Frontiers in Public Health|November 21, 2022
The impact of agricultural disasters on child development in rural ChinaSipei Xu, Peng Zhan
Current Pharmaceutical Design|July 18, 2013
Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activitiesYu'ning Song, Peng Zhan, Xinyong Liu
Science Bulletin|January 20, 2023
Reducing energy barriers of chemical reactions with a nanomicrocell catalyst consisting of integrated active sites in conductive matricesGuo-Peng Zhan, Chuan-De Wu
International Journal of Genomics|October 1, 2025
NRG-1 Promotes Axon Regeneration of Dorsal Root Ganglion Neurons in Diabetic Rats via ITGB1/FAK/AKT PathwayPeng Zhan, Hewei Xiong, Hongmei Zheng
Mini Reviews in Medicinal Chemistry|April 23, 2010
Naturally occurring and synthetic bioactive molecules as novel non-nucleoside HBV inhibitorsPeng Zhan, Xuemei Jiang, Xinyong Liu
Mini Reviews in Medicinal Chemistry|June 15, 2010
Cosalane and its analogues: a unique class of anti-HIV agentsPeng Zhan, Zhenyu Li, Xinyong Liu
Current Medicinal Chemistry|August 20, 2009
Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 updatePeng Zhan, Xinyong Liu, Zhenyu Li
Journal of Medicinal Chemistry|March 28, 2019
Resurrecting the Condemned: Identification of N-Benzoxaborole Benzofuran GSK8175 as a Clinical Candidate with Reduced Metabolic LiabilityPeng Zhan, Dongwei Kang, Xinyong Liu
Pageof 56